Amarin (AMRN) stock falls even as the company beats Q4 forecasts amid its plans to implement a 20:1 ADS ratio change to maintain Nasdaq listing. Read more here.

European equities traded in the US as American depositary receipts were up sharply late Friday morning, rising 1.47% to 1,411.02 on the S&P Europe Select ADR Index. Despite the gain, the index is down ...

Amarin has a 52 week low of $0.43 and a 52 week high of $1.11. The company has a market cap of $217.66 million, a PE ratio of -5.89 and a beta of 1.82. Amarin Corporation plc, a pharmaceutical ...

“Amarin strongly disagrees with the ruling ... Neurotech's cell therapy gets FDA nod for eye disorder MacTe... Neurotech Pharma's cell therapy Encelto has become the first FDA-approved ...

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin's Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high ...

Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Austria’s Health Authorities have approved VAZKEPA® for ...

US appeals court revives Amarin heart-drug patent lawsuit over Hikma generic Amarin Pharma convinced a U.S. appeals court on Tuesday to resurrect a patent infringement lawsuit over Hikma ...

Effective 1 April 2025, Austrian Reimbursement Marks 10th National Reimbursement for VAZKEPA® in Europe, Supporting Amarin’s Continued Growth and Development Across the Continent -- DUBLIN ...